How to Develop a National Formulary Based on the WHO Model Formulary - A Practical Guide
(2004; 45 pages) Voir le document au format PDF
Table des matières
Afficher le documentAbbreviations
Ouvrir ce répertoire et afficher son contenu1 INTRODUCTION
Ouvrir ce répertoire et afficher son contenu2 OVERVIEW OF THE NATIONAL FORMULARY PROCESS
Fermer ce répertoire3 DEVELOPING THE PRELIMINARY INFORMATION SECTION
Afficher le documentDeveloping locally relevant introductory information
Ouvrir ce répertoire et afficher son contenuGeneral entries at the front of a national formulary
Fermer ce répertoireAdditional information at the front of the national formulary
Afficher le documentInstructions on how to use the formulary
Afficher le documentGlossary
Afficher le documentPolicies and procedures of the national formulary and national formulary committee
Afficher le documentNational policies and regulations
Afficher le documentList of changes
Afficher le documentAdapting the “General advice to prescribers” section of the WHO model formulary
Ouvrir ce répertoire et afficher son contenu4 DEVELOPMENT OF THERAPEUTIC INFORMATION AND MONOGRAPHS USING THE WHO MODEL FORMULARY
Ouvrir ce répertoire et afficher son contenu5 ADDITIONAL SOURCES OF INFORMATION
Ouvrir ce répertoire et afficher son contenu6 DEVELOPING SPECIFIC INFORMATION SECTIONS
Ouvrir ce répertoire et afficher son contenu7 PRODUCTION, DISTRIBUTION AND IMPLEMENTATION
Ouvrir ce répertoire et afficher son contenu8 EVALUATION
Ouvrir ce répertoire et afficher son contenu9 REVIEW AND UPDATE
Afficher le documentREFERENCES
 

National policies and regulations

The following items can be included as separate sections, or some of them may be adapted from the “General advice to prescribers” section of the WMF:

- guidelines for prescribers on national requirements on prescription writing, prescribing dangerous or controlled preparations, principles of rational drug use, prescribing for patients with special needs (children, the elderly, pregnant and lactating women, those with renal and hepatic disease, and those requiring intensive and palliative care);

- guidelines on good dispensing practices including checking prescriptions, accuracy of dispensing, labelling, packaging and patient counselling;

- reporting of adverse drug reactions; and

- reporting of defective medicines or counterfeit products.

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013